[Association of cerebrospinal fluid status with prognosis in children with acute lymphoblastic leukemia]. 2020

Wen-Yu Yang, and Ye Guo, and Xiao-Juan Chen, and Li-Peng Liu, and Tian-Feng Liu, and Fang Liu, and Min Ruan, and Shu-Chun Wang, and Li Zhang, and Xiao-Ming Liu, and Ben-Quan Qi, and Li-Xian Chang, and Yao Zou, and Yu-Mei Chen, and Xiao-Fan Zhu
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China. xfzhu@ihcams.ac.cn.

OBJECTIVE To study the clinical features of central nervous system infiltration-positive (CNSI+) children with acute lymphoblastic leukemia (ALL) based on flow cytometry, as well as the association of such clinical features with prognosis. METHODS A retrospective analysis was performed for the clinical data of 66 CNSI+ children with ALL treated from April 2008 to June 2013. Clinical features, laboratory examination results and prognosis were compared between the children in different chemotherapy stages (induction stage and consolidation/maintenance stage). RESULTS Among the 66 CNSI+ children, 50 were in the induction stage and 16 in the consolidation/maintenance stage. Compared with the CNSI+ children in the induction stage, the CNSI+ children in the consolidation/maintenance stage had a significantly higher proportion of children with the genes associated with good prognosis based on the results of molecular biology (P<0.05), as well as a significantly higher recurrence rate (P<0.05). Recurrence was observed in 21 CNSI+ ALL children, among whom 10 were in the induction stage and 11 were in the consolidation/maintenance stage. Compared with the children experiencing recurrence in the induction stage, the children experiencing recurrence in the consolidation/maintenance stage had a significantly higher proportion of children with recurrence of the central nervous system and bone marrow (P<0.05), as well as significantly higher proportion of biochemical positive rate of cerebrospinal fluid (P<0.05). The children in the induction stage had a significantly higher recurrence-free survival rate than those in the consolidation/maintenance stage (P<0.001), while there was no significant difference in overall survival rate between the two groups (P>0.05). CONCLUSIONS In children with ALL, CNSI+ has a marked effect on recurrence-free survival rate in different chemotherapy stages, but has no obvious effect on overall survival rate. CNSI+ patients in the consolidation/maintenance stage have a higher recurrence.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D054198 Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias. Leukemia, Lymphoblastic,Leukemia, Lymphoid, Acute,Lymphoblastic Leukemia,Lymphoblastic Lymphoma,Lymphocytic Leukemia, Acute,Lymphoma, Lymphoblastic,ALL, Childhood,Acute Lymphoid Leukemia,Leukemia, Acute Lymphoblastic,Leukemia, Lymphoblastic, Acute,Leukemia, Lymphoblastic, Acute, L1,Leukemia, Lymphoblastic, Acute, L2,Leukemia, Lymphoblastic, Acute, Philadelphia-Positive,Leukemia, Lymphocytic, Acute,Leukemia, Lymphocytic, Acute, L1,Leukemia, Lymphocytic, Acute, L2,Lymphoblastic Leukemia, Acute,Lymphoblastic Leukemia, Acute, Adult,Lymphoblastic Leukemia, Acute, Childhood,Lymphoblastic Leukemia, Acute, L1,Lymphoblastic Leukemia, Acute, L2,Lymphocytic Leukemia, L1,Lymphocytic Leukemia, L2,Acute Lymphoblastic Leukemia,Acute Lymphocytic Leukemia,Childhood ALL,L1 Lymphocytic Leukemia,L2 Lymphocytic Leukemia,Leukemia, Acute Lymphocytic,Leukemia, Acute Lymphoid,Leukemia, L1 Lymphocytic,Leukemia, L2 Lymphocytic,Lymphoid Leukemia, Acute,Precursor Cell Lymphoblastic Leukemia Lymphoma
D018572 Disease-Free Survival Period after successful treatment in which there is no appearance of the symptoms or effects of the disease. Survival, Disease-Free,Disease Free Survival,Survival, Disease Free

Related Publications

Wen-Yu Yang, and Ye Guo, and Xiao-Juan Chen, and Li-Peng Liu, and Tian-Feng Liu, and Fang Liu, and Min Ruan, and Shu-Chun Wang, and Li Zhang, and Xiao-Ming Liu, and Ben-Quan Qi, and Li-Xian Chang, and Yao Zou, and Yu-Mei Chen, and Xiao-Fan Zhu
September 1977, Pediatria polska,
Wen-Yu Yang, and Ye Guo, and Xiao-Juan Chen, and Li-Peng Liu, and Tian-Feng Liu, and Fang Liu, and Min Ruan, and Shu-Chun Wang, and Li Zhang, and Xiao-Ming Liu, and Ben-Quan Qi, and Li-Xian Chang, and Yao Zou, and Yu-Mei Chen, and Xiao-Fan Zhu
August 1974, The Journal of pediatrics,
Wen-Yu Yang, and Ye Guo, and Xiao-Juan Chen, and Li-Peng Liu, and Tian-Feng Liu, and Fang Liu, and Min Ruan, and Shu-Chun Wang, and Li Zhang, and Xiao-Ming Liu, and Ben-Quan Qi, and Li-Xian Chang, and Yao Zou, and Yu-Mei Chen, and Xiao-Fan Zhu
January 1989, International journal of cancer,
Wen-Yu Yang, and Ye Guo, and Xiao-Juan Chen, and Li-Peng Liu, and Tian-Feng Liu, and Fang Liu, and Min Ruan, and Shu-Chun Wang, and Li Zhang, and Xiao-Ming Liu, and Ben-Quan Qi, and Li-Xian Chang, and Yao Zou, and Yu-Mei Chen, and Xiao-Fan Zhu
June 2023, Zhongguo shi yan xue ye xue za zhi,
Wen-Yu Yang, and Ye Guo, and Xiao-Juan Chen, and Li-Peng Liu, and Tian-Feng Liu, and Fang Liu, and Min Ruan, and Shu-Chun Wang, and Li Zhang, and Xiao-Ming Liu, and Ben-Quan Qi, and Li-Xian Chang, and Yao Zou, and Yu-Mei Chen, and Xiao-Fan Zhu
September 1981, Pediatria polska,
Wen-Yu Yang, and Ye Guo, and Xiao-Juan Chen, and Li-Peng Liu, and Tian-Feng Liu, and Fang Liu, and Min Ruan, and Shu-Chun Wang, and Li Zhang, and Xiao-Ming Liu, and Ben-Quan Qi, and Li-Xian Chang, and Yao Zou, and Yu-Mei Chen, and Xiao-Fan Zhu
January 1982, Acta haematologica Polonica,
Wen-Yu Yang, and Ye Guo, and Xiao-Juan Chen, and Li-Peng Liu, and Tian-Feng Liu, and Fang Liu, and Min Ruan, and Shu-Chun Wang, and Li Zhang, and Xiao-Ming Liu, and Ben-Quan Qi, and Li-Xian Chang, and Yao Zou, and Yu-Mei Chen, and Xiao-Fan Zhu
October 2006, Leukemia research,
Wen-Yu Yang, and Ye Guo, and Xiao-Juan Chen, and Li-Peng Liu, and Tian-Feng Liu, and Fang Liu, and Min Ruan, and Shu-Chun Wang, and Li Zhang, and Xiao-Ming Liu, and Ben-Quan Qi, and Li-Xian Chang, and Yao Zou, and Yu-Mei Chen, and Xiao-Fan Zhu
January 1993, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,
Wen-Yu Yang, and Ye Guo, and Xiao-Juan Chen, and Li-Peng Liu, and Tian-Feng Liu, and Fang Liu, and Min Ruan, and Shu-Chun Wang, and Li Zhang, and Xiao-Ming Liu, and Ben-Quan Qi, and Li-Xian Chang, and Yao Zou, and Yu-Mei Chen, and Xiao-Fan Zhu
January 1989, Acta haematologica Polonica,
Wen-Yu Yang, and Ye Guo, and Xiao-Juan Chen, and Li-Peng Liu, and Tian-Feng Liu, and Fang Liu, and Min Ruan, and Shu-Chun Wang, and Li Zhang, and Xiao-Ming Liu, and Ben-Quan Qi, and Li-Xian Chang, and Yao Zou, and Yu-Mei Chen, and Xiao-Fan Zhu
October 2010, Journal of clinical medicine research,
Copied contents to your clipboard!